Editas Medicine gets trial approval for EDIT-401
- Phase 1/2 Strive trial approved in Australia
- EDIT-401 aims to reduce LDL-C by 90%
- Trial to start in 2026, data due Q1 2027
Every EDGAR filing for Editas Medicine, Inc. (EDIT), newest first, with AI summaries and stories.
Next: earnings expected ~Nov 9 · 10-Q expected ~Nov 9 (deadline Nov 16)
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Daniel Scott Ory, insider filing for EDIT
Daniel Scott Ory, reporting
Linda Burkly, insider filing for EDIT
Linda Burkly, reporting
Gilmore Neil O'Neill, planned sale of EDIT shares
Gilmore Neil O'Neill, reporting
Ownership stake disclosure by ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC, filed by
Patrick Thomas Ellinor II, insider filing for EDIT
Patrick Thomas Ellinor II, reporting
Amy Parison, insider filing for EDIT
Amy Parison, reporting
Linda Burkly, insider filing for EDIT
Linda Burkly, reporting
Ownership stake disclosure by BlackRock, Inc. (amended)
BlackRock, Inc., filed by
Linda Burkly, planned sale of EDIT shares
Linda Burkly, reporting
Bernadette Connaughton, insider filing for EDIT
Bernadette Connaughton, reporting
Amy Parison, insider filing for EDIT
Amy Parison, reporting
Ownership stake disclosure by RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P., filed by
Ownership stake disclosure by Commodore Capital LP
Commodore Capital LP, filed by
Gilmore Neil O'Neill, planned sale of EDIT shares
Gilmore Neil O'Neill, reporting
Ownership stake disclosure by VANGUARD GROUP INC (amended)
VANGUARD GROUP INC, filed by
Gilmore Neil O'Neill, insider filing for EDIT
Gilmore Neil O'Neill, reporting